| Date Filed | Type | Description |
| 01/29/2013 |
SC 13D/A
| Hunter Robert Merrill reports a 0% stake in Callisto Pharmaceuticals, Inc. |
| 01/22/2013 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 01/15/2013 |
8-K
| Quarterly results |
| 01/03/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/03/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/03/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 12/07/2012 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 11/19/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/14/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 10/16/2012 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 10/16/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/28/2012 |
10-Q/A
| Quarterly Report for the period ended June 30, 2012 [amend] |
| 08/20/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/14/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 07/23/2012 |
8-K
| Form 8-K - Current report |
| 07/23/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 05/15/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 03/30/2012 |
10-K
| Annual Report for the period ended December 31, 2011 |
| 03/28/2012 |
SC 13D/A
| Hunter Robert Merrill reports a 16.1% stake in Callisto Pharmaceuticals, Inc. |
| 11/14/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 08/15/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 08/03/2011 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/03/2011 |
BW
| Synergy Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference |
| 05/18/2011 |
BW
| Synergy Pharmaceuticals Advances Its Preclinical Research Program For The Use Of Guanylate Cyclase C Agonists To Lower Cholesterol |
| 05/16/2011 |
10-Q
| Quarterly Report for the period ended March 31, 2011 |
| 05/03/2011 |
BW
| Synergy Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference |
| 04/19/2011 |
8-K
| Form 8-K - Current report |
| 03/31/2011 |
10-K
| Annual Report for the period ended December 31, 2010 |
| 03/22/2011 |
BW
| Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations |
| 03/08/2011 |
BW
| Synergy Pharmaceuticals to Present at BIO-Europe Spring 2011 Conference |
| 02/23/2011 |
BW
| Synergy Pharmaceuticals Granted U.S. Patent on SP-333, Synergy's Developmental Drug for Gastrointestinal Inflammatory Diseases |
| 12/21/2010 |
SC 13D/A
| Hunter Robert Merrill reports a 23.7% stake in Callisto Pharmaceuticals, Inc. |
| 12/20/2010 |
SC 13D
| Hunter Robert Merrill reports a 23.5% stake in Callisto Pharmaceuticals, Inc. |
| 12/16/2010 |
8-K
| Form 8-K - Current report |
|